{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:56:08Z","timestamp":1757624168701,"version":"3.44.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":44,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.gastha.2023.02.005","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T20:54:12Z","timestamp":1676580852000},"page":"547-548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of Hepatorenal Syndrome-Acute Kidney Injury: Advances Made but Challenges Remain"],"prefix":"10.1016","volume":"2","author":[{"given":"Madhumita","family":"Premkumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Rajender","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.gastha.2023.02.005_bib1","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa2008290","article-title":"Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome","volume":"384","author":"Wong","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.gastha.2023.02.005_bib2","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/apt.17195","article-title":"Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure","volume":"56","author":"Wong","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.gastha.2023.02.005_bib3","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.gastha.2023.01.007","article-title":"Vasoconstrictor therapy for Acute kidney injury hepatorenal syndrome: a meta-analysis of randomized studies","volume":"2","author":"Singal","year":"2023","journal-title":"Gastro Hep Advances"},{"issue":"1","key":"10.1016\/j.gastha.2023.02.005_bib4","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1038\/s41598-022-09505-1","article-title":"Safety and efficacy of terlipressin in acute-on-chronic liver failure with hepatorenal syndrome-acute kidney injury (HRS-AKI): a prospective cohort study","volume":"12","author":"Kulkarni","year":"2022","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.gastha.2023.02.005_bib5","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/hep.30208","article-title":"Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure","volume":"71","author":"Arora","year":"2020","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.gastha.2023.02.005_bib6","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/hep.28396","article-title":"Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study","volume":"63","author":"Cavallin","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.gastha.2023.02.005_bib7","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/hep.27006","article-title":"Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage","volume":"60","author":"Seo","year":"2014","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.gastha.2023.02.005_bib8","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.cgh.2018.01.035","article-title":"Association between grade of acute on chronic liver failure and response to terlipressin and albumin in patients with hepatorenal syndrome","volume":"16","author":"Piano","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.gastha.2023.02.005_bib9","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jceh.2018.08.008","article-title":"Left ventricular diastolic dysfunction is associated with renal dysfunction, poor survival and low health related quality of life in cirrhosis","volume":"9","author":"Premkumar","year":"2019","journal-title":"J\u00a0Clin Exp Hepatol"},{"issue":"1","key":"10.1016\/j.gastha.2023.02.005_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/hep.23283","article-title":"Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome","volume":"51","author":"Nazar","year":"2010","journal-title":"Hepatology"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572323000298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572323000298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T11:34:55Z","timestamp":1757417695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572323000298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"alternative-id":["S2772572323000298"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2023.02.005","relation":{},"ISSN":["2772-5723"],"issn-type":[{"type":"print","value":"2772-5723"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Hepatorenal Syndrome-Acute Kidney Injury: Advances Made but Challenges Remain","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2023.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2023.01.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}